Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
4D Molecular Therapeutics, Inc. (FDMT)
USD11.48
-0.22 (-1.88%)
US NASDAQ Healthcare Biotechnology
Address
5858 Horton Street 94608
EmeryVille, CA, US
EmeryVille, CA, US
CEO
David H. Kirn
Website
4dmoleculartherapeutics.com
IPO
2020-12-11
CIK 1650648 ISIN US35104E1001
Description
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD11.48
-0.22 (-1.88%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
864.8K
Beta
2.69
Float Shares
35.26M
Free Float %
67.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.17% | +13.88% | +2.99% | +10.59% | +0.58% | +37.87% | +216.21% | -41.98% | -60.86% | -74.47% | -74.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
11.48
Low
33.00
+187.4%
Consensus
33.00
+187.4%
Median
33.00
+187.4%
High
33.00
+187.4%
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 7 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
25.33
+120.6%
|
| All Time | 15 |
38.60
+236.2%
|
Quality scores
Altman Z-Score
3.26
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+230,194.6% ★ Q1'26: +21,664.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+18.8% Q1'26: -17.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-171.7% Q1'26: -2,235.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-187.2% Q1'26: -2,416.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-128.2% Q1'26: -361.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.4% Q1'26: +22.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.14× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 4 Rev. Ana. 5 EPS Ana. |
Dec 2028 6 Rev. Ana. 4 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.61M
est: 15.21M (-10.5%)
|
18.04M
est: 18.83M (-4.2%)
|
3.13M
est: 2.63M (+18.8%)
|
20.72M
est: 20.22M (+2.5%)
|
37.0K
est: 1.28M (-97.1%)
|
85.21M
est: 33.54M (+154.1%)
|
10.21M
67.8K – 20.35M
-69.6% YoY
|
14.82M
92.9K – 29.55M
+45.2% YoY
|
41.43M
39.22M – 43.65M
+179.6% YoY
|
137.08M
884.4K – 273.27M
+230.8% YoY
|
295.86M
1.91M – 589.82M
+115.8% YoY
|
| EBITDA |
-55.22M
est: -15.21M (-263.1%)
|
-69.81M
est: -18.83M (-270.7%)
|
-107.63M
est: -2.63M (-3,987.2%)
|
-108.66M
est: -20.22M (-437.5%)
|
-181.14M
est: -1.28M (-13,998.4%)
|
-151.92M
est: -33.54M (-353.0%)
|
-10.21M
-20.35M – -67.8K
+69.6% YoY
|
-14.82M
-29.55M – -92.9K
-45.2% YoY
|
-41.43M
-43.65M – -39.22M
-179.6% YoY
|
-137.08M
-273.27M – -884.4K
-230.8% YoY
|
-295.86M
-589.82M – -1.91M
-115.8% YoY
|
| EBIT |
-56.66M
est: -15.21M (-272.6%)
|
-71.33M
est: -18.83M (-278.8%)
|
-110.03M
est: -2.63M (-4,078.4%)
|
-112.87M
est: -20.22M (-458.3%)
|
-187.84M
est: -1.28M (-14,520.3%)
|
-159.55M
est: -33.54M (-375.7%)
|
-10.21M
-20.35M – -67.8K
+69.6% YoY
|
-14.82M
-29.55M – -92.9K
-45.2% YoY
|
-41.43M
-43.65M – -39.22M
-179.6% YoY
|
-137.08M
-273.27M – -884.4K
-230.8% YoY
|
-295.86M
-589.82M – -1.91M
-115.8% YoY
|
| Net Income |
-56.69M
est: -142.23M (+60.1%)
|
-71.32M
est: -150.10M (+52.5%)
|
-107.49M
est: -111.37M (+3.5%)
|
-100.84M
est: -109.89M (+8.2%)
|
-160.87M
est: -165.85M (+3.0%)
|
-140.11M
est: -140.11M (+0.0%)
|
-248.81M
-261.95M – -165.44M
-77.6% YoY
|
-208.46M
-254.55M – -162.37M
+16.2% YoY
|
-280.98M
-356.68M – -152.44M
-34.8% YoY
|
-189.14M
-433.44M – 55.16M
+32.7% YoY
|
-124.26M
-284.76M – 36.24M
+34.3% YoY
|
| SGA |
17.24M
est: 3.88B (-99.6%)
|
28.01M
est: 4.80B (-99.4%)
|
32.91M
est: 670.97M (-95.1%)
|
36.49M
est: 5.15B (-99.3%)
|
46.58M
est: 327.19M (-85.8%)
|
49.06M
est: 8.54B (-99.4%)
|
2.60B
17.27M – 5.18B
-69.6% YoY
|
3.77B
23.66M – 7.52B
+45.2% YoY
|
10.55B
9.99B – 11.11B
+179.6% YoY
|
34.91B
225.22M – 69.59B
+230.8% YoY
|
75.34B
486.09M – 150.20B
+115.8% YoY
|
| EPS |
-2.12
est: -2.64 (+19.6%)
|
-2.46
est: -2.78 (+11.6%)
|
-3.12
est: -3.17 (+1.7%)
|
-2.58
est: -2.32 (-11.4%)
|
-2.98
est: -2.91 (-2.4%)
|
-2.42
est: -3.26 (+25.7%)
|
-3.84
-4.52 – -2.86
-17.8% YoY
|
-3.67
-4.39 – -2.80
+4.3% YoY
|
-3.68
-6.16 – -2.63
-0.3% YoY
|
-3.27
-7.48 – 0.95
+11.3% YoY
|
-2.15
-4.92 – 0.63
+34.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-26.15M
OE per share TTM
-0.33
Owner's Yield
-3.87%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
122.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
25
Total invested
9.66M
Insider transactions (90d)
0
Beneficial owners (>5%)
39
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BVF Inc. | 4.01M | 12.40% | — | — | — | 4.01M | CO | Delaware | 2022-06-21 | ↗ |
| 2 | BVF Partners L.P. | 4.01M | 12.40% | — | — | — | 4.01M | IA, PN | Delaware | 2022-06-21 | ↗ |
| 3 | Mark N. Lampert | 4.01M | 12.40% | — | — | — | 4.01M | IN | Delaware | 2022-06-21 | ↗ |
| 4 | BVF GP Holdings LLC | 3.70M | 11.50% | — | — | — | 3.70M | OO | Delaware | 2022-06-21 | ↗ |
| 5 | GOLDMAN SACHS & CO. LLC | 3.59M | 6.90% | — | 3.59M | — | 3.59M | BD, IA, OO | — | 2024-11-06 | ↗ |
| 6 | THE GOLDMAN SACHS GROUP, INC. | 3.59M | 6.90% | — | 3.59M | — | 3.59M | HC, CO | — | 2024-11-06 | ↗ |
| 7 | Koh, Bong | 2.89M | 8.70% | — | 2.89M | — | 2.89M | IN | United States | 2023-05-15 | ↗ |
| 8 | Shah, Nimish | 2.89M | 8.70% | — | 2.89M | — | 2.89M | IN | United States | 2023-05-15 | ↗ |
| 9 | VHCP Co-Investment Holdings III, LLC | 2.89M | 8.70% | — | 2.89M | — | 2.89M | OO | Delaware | 2023-05-15 | ↗ |
| 10 | VHCP Management EG, LLC | 2.89M | 8.70% | — | 2.89M | — | 2.89M | OO | Delaware | 2023-05-15 | ↗ |
| 11 | VHCP Management III, LLC | 2.89M | 8.70% | — | 2.89M | — | 2.89M | OO | Delaware | 2023-05-15 | ↗ |
| 12 | Venrock Healthcare Capital Partners EG, L.P. | 2.89M | 8.70% | — | 2.89M | — | 2.89M | PN | Delaware | 2023-05-15 | ↗ |
| 13 | Venrock Healthcare Capital Partners III, L.P. | 2.89M | 8.70% | — | 2.89M | — | 2.89M | PN | Delaware | 2023-05-15 | ↗ |
| 14 | Peter Kolchinsky | 2.79M | 6.70% | — | 2.79M | — | — | HC, IN | Delaware | 2023-06-05 | ↗ |
| 15 | RA Capital Healthcare Fund, L.P. | 2.79M | 6.70% | — | 2.79M | — | — | PN | Delaware | 2023-06-05 | ↗ |
| 16 | RA Capital Management, L.P. | 2.79M | 6.70% | — | 2.79M | — | — | IA, PN | Delaware | 2023-06-05 | ↗ |
| 17 | Rajeev Shah | 2.79M | 6.70% | — | 2.79M | — | — | HC, IN | Delaware | 2023-06-05 | ↗ |
| 18 | BVF I GP LLC | 2.13M | 6.60% | — | — | — | 2.13M | OO | Delaware | 2022-06-21 | ↗ |
| 19 | Biotechnology Value Fund, L.P. | 2.13M | 6.60% | — | — | — | 2.13M | PN | Delaware | 2022-06-21 | ↗ |
| 20 | (1) BlackRock, Inc. | 2.09M | 6.50% | 2.05M | — | 2.09M | — | HC | Delaware | 2022-02-04 | ↗ |
| 21 | David Kirn | 2.03M | 6.30% | 2.03M | — | 2.03M | — | IN | United States | 2022-02-14 | ↗ |
| 22 | 10 | 2.00M | 7.50% | 2.00M | — | 2.00M | — | IN | — | 2021-02-16 | ↗ |
| 23 | David Kroin | 1.80M | 5.69% | — | 1.80M | — | — | HC, IN | Delaware | 2021-11-04 | ↗ |
| 24 | Deep Track Biotechnology Master Fund, Ltd. | 1.80M | 5.69% | — | 1.80M | — | — | CO | Delaware | 2021-11-04 | ↗ |
| 25 | Deep Track Capital, LP | 1.80M | 5.69% | — | 1.80M | — | — | IA, OO | Delaware | 2021-11-04 | ↗ |
| 26 | Pfizer Inc. | 1.67M | 6.30% | 343.6K | 1.32M | 343.6K | — | CO | Delaware | 2021-02-16 | ↗ |
| 27 | EIN #00-0000000 | 1.65M | 5.10% | — | 1.65M | — | 1.65M | IA, HC | Jersey, Channel Islands | 2022-02-11 | ↗ |
| 28 | Abigail P. Johnson | 1.59M | 7.38% | — | — | 1.59M | — | IN | United States of America | 2021-02-08 | ↗ |
| 29 | FMR LLC | 1.59M | 7.38% | 227.3K | — | 1.59M | — | HC | Delaware | 2021-02-08 | ↗ |
| 30 | BVF II GP LLC | 1.57M | 4.90% | — | — | — | 1.57M | OO | Delaware | 2022-06-21 | ↗ |
| 31 | Biotechnology Value Fund II, L.P. | 1.57M | 4.90% | — | — | — | 1.57M | PN | Delaware | 2022-06-21 | ↗ |
| 32 | Ridgeback Capital Investments Ltd. 00-0000000 | 1.44M | 5.40% | — | 1.44M | — | 1.44M | OO | Cayman Islands | 2020-12-23 | ↗ |
| 33 | Ridgeback Capital Management LLC 42-1684320 | 1.44M | 5.40% | — | 1.44M | — | 1.44M | OO | Delaware | 2020-12-23 | ↗ |
| 34 | Pfizer Ventures (US) LLC | 1.32M | 5.00% | — | 1.32M | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 35 | David Schaffer | 901.2K | 2.80% | 901.2K | — | 901.2K | — | IN | — | 2022-02-14 | ↗ |
| 36 | Pfizer Inc. 13-5315170 | 341.7K | 1.06% | — | 341.7K | — | — | CO | — | 2022-02-11 | ↗ |
| 37 | Pfizer Ventures (US) LLC 82-5524518 | 341.7K | 1.06% | — | 341.7K | — | — | OO | — | 2022-02-11 | ↗ |
| 38 | BVF Partners OS Ltd. | 209.7K | 1.00% | — | — | — | 209.7K | CO | Delaware | 2022-06-21 | ↗ |
| 39 | Biotechnology Value Trading Fund OS LP | 209.7K | 1.00% | — | — | — | 209.7K | PN | Delaware | 2022-06-21 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
25
-130 vs prev Q
New positions
5
Closed positions
130
Increased
11
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 5.65M +1.1M (+23.9%) | 42.40M +2.7M (+6.9%) | 10.07% +1.913 pp | 0.43% -0.054 pp | USD16.81 -55.4% | 11 qtrs — |
| 2 | JANUS HENDERSON GROUP PLC | 4.64M +2.9M (+164.4%) | 34.73M +19.5M (+127.9%) | 8.26% +5.125 pp | 0.02% +0.009 pp | USD14.58 -48.6% | 21 qtrs — |
| 3 | BVF INC/IL | 4.63M +— (+0.0%) | 34.72M -5.5M (-13.7%) | 8.25% -0.029 pp | 1.17% -0.462 pp | USD10.84 -30.8% | 21 qtrs — |
| 4 | GOLDMAN SACHS GROUP INC | 4.30M +174.5K (+4.2%) | 32.27M -3.6M (-10.0%) | 7.67% +0.285 pp | 0.00% 0.000 pp | USD21.83 -65.6% | 21 qtrs — |
| 5 | BLACKROCK, INC. | 4.06M +195.7K (+5.1%) | 30.49M -3.1M (-9.3%) | 7.24% +0.324 pp | 0.00% 0.000 pp | USD10.60 -29.2% | 6 qtrs — |
| 6 | NOVO HOLDINGS A/S | 3.65M +1.7M (+82.5%) | 27.38M +10.0M (+57.5%) | 6.50% +2.928 pp | 2.13% +1.006 pp | USD10.80 -30.6% | 12 qtrs — |
| 7 | VANGUARD GROUP INC | 3.09M +518.4K (+20.1%) | 23.20M +823.6K (+3.7%) | 5.51% +0.907 pp | 0.00% +0.000 pp | USD21.56 -65.2% | 21 qtrs — |
| 8 | STATE STREET CORP | 2.69M +1.8M (+197.5%) | 20.17M +12.3M (+156.8%) | 4.79% +3.175 pp | 0.00% +0.000 pp | USD12.68 -40.9% | 20 qtrs — |
| 9 | ARMISTICE CAPITAL, LLC | 1.94M +840.0K (+76.6%) | 14.52M +5.0M (+52.5%) | 3.45% +1.490 pp | 0.17% +0.032 pp | USD8.50 -11.8% | 6 qtrs — |
| 10 | FEDERATED HERMES, INC. | 1.61M +14.7K (+0.9%) | 12.07M -1.8M (-12.9%) | 2.87% +0.016 pp | 0.02% -0.004 pp | USD3.39 +121.2% | 5 qtrs — |
| 11 | POINT72 ASSET MANAGEMENT, L.P. | 1.54M +1.5M (+100.0%) | 11.55M +11.5M (+100.0%) | 2.74% +2.744 pp | 0.01% +0.013 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.24M +1.1M (+605.8%) | 9.26M +7.7M (+509.2%) | 2.20% +1.888 pp | 0.01% +0.012 pp | USD7.67 -2.2% | 2 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 1.01M +98.5K (+10.8%) | 7.59M -348.6K (-4.4%) | 1.80% +0.170 pp | 0.00% +0.000 pp | USD23.00 -67.4% | 21 qtrs — |
| 14 | EVERGREEN QUALITY FUND GP, LTD. | 951.5K +951.5K (+100.0%) | 7.14M +7.1M (+100.0%) | 1.70% +1.695 pp | 0.14% +0.141 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 15 | BANK OF AMERICA CORP /DE/ | 832.6K +13.3K (+1.6%) | 6.24M -875.0K (-12.3%) | 1.48% +0.019 pp | 0.00% +0.000 pp | USD4.59 +63.4% | 21 qtrs — |
| 16 | DEUTSCHE BANK AG\ | 704.2K +160.9K (+29.6%) | 5.28M +560.0K (+11.9%) | 1.25% +0.283 pp | 0.00% +0.000 pp | USD9.57 -21.6% | 20 qtrs — |
| 17 | MORGAN STANLEY | 672.7K -163.2K (-19.5%) | 5.05M -2.2M (-30.5%) | 1.20% -0.296 pp | 0.00% 0.000 pp | USD12.29 -39.0% | 21 qtrs — |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 512.9K +199.7K (+63.8%) | 3.85M +1.1M (+41.3%) | 0.91% +0.354 pp | 0.01% +0.002 pp | USD7.08 +5.9% | 4 qtrs — |
| 19 | PARKMAN HEALTHCARE PARTNERS LLC | 503.4K +303.4K (+151.7%) | 3.78M +2.0M (+117.2%) | 0.90% +0.539 pp | 0.36% +0.178 pp | USD7.97 -5.9% | 2 qtrs — |
| 20 | ARROWMARK COLORADO HOLDINGS LLC | 485.4K -18.7K (-3.7%) | 3.64M -740.3K (-16.9%) | 0.86% -0.037 pp | 0.08% -0.001 pp | USD28.48 -73.7% | 21 qtrs — |
| 21 | RAYMOND JAMES FINANCIAL INC | 477.5K +6.2K (+1.3%) | 3.58M -514.0K (-12.6%) | 0.85% +0.008 pp | 0.00% 0.000 pp | USD4.18 +79.4% | 5 qtrs — |
| 22 | RTW INVESTMENTS, LP | 475.7K +475.7K (+100.0%) | 3.57M +3.6M (+100.0%) | 0.85% +0.848 pp | 0.04% +0.036 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 23 | BAKER BROS. ADVISORS LP | 475.7K +475.7K (+100.0%) | 3.57M +3.6M (+100.0%) | 0.85% +0.848 pp | 0.02% +0.021 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 353.4K +47.5K (+15.5%) | 2.65M -7.5K (-0.3%) | 0.63% +0.083 pp | 0.00% +0.000 pp | USD21.43 -65.0% | 20 qtrs — |
| 25 | TWO SIGMA INVESTMENTS, LP | 337.5K +64.0K (+23.4%) | 2.53M +154.6K (+6.5%) | 0.60% +0.112 pp | 0.00% +0.000 pp | USD6.87 +9.2% | 17 qtrs — |
| 26 | NORTHERN TRUST CORP | 313.8K -21.8K (-6.5%) | 2.35M -562.6K (-19.3%) | 0.56% -0.041 pp | 0.00% 0.000 pp | USD23.24 -67.7% | 20 qtrs — |
| 27 | ASSENAGON ASSET MANAGEMENT S.A. | 296.2K -367.5K (-55.4%) | 2.22M -3.5M (-61.5%) | 0.53% -0.659 pp | 0.00% -0.005 pp | USD16.17 -53.6% | 8 qtrs — |
| 28 | DIMENSIONAL FUND ADVISORS LP | 294.8K +236.8K (+408.3%) | 2.21M +1.7M (+339.2%) | 0.53% +0.422 pp | 0.00% +0.000 pp | USD9.33 -19.6% | 12 qtrs — |
| 29 | JPMORGAN CHASE & CO | 279.5K -234.0K (-45.6%) | 2.10M -2.4M (-53.0%) | 0.50% -0.420 pp | 0.00% 0.000 pp | USD9.97 -24.8% | 20 qtrs — |
| 30 | TWO SIGMA ADVISERS, LP | 275.3K -274.4K (-49.9%) | 2.06M -2.7M (-56.8%) | 0.49% -0.492 pp | 0.00% -0.006 pp | USD3.95 +89.9% | 6 qtrs — |
| 31 | BURKEHILL GLOBAL MANAGEMENT, LP | 275.0K +275.0K (+100.0%) | 2.06M +2.1M (+100.0%) | 0.49% +0.490 pp | 0.14% +0.136 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 32 | PEAPOD LANE CAPITAL LLC | 268.0K -54.1K (-16.8%) | 2.01M -788.5K (-28.2%) | 0.48% -0.098 pp | 1.71% -0.793 pp | USD4.52 +65.9% | 5 qtrs — |
| 33 | UBS GROUP AG | 231.3K +136.4K (+143.7%) | 1.73M +910.0K (+110.3%) | 0.41% +0.242 pp | 0.00% +0.000 pp | USD8.86 -15.3% | 13 qtrs — |
| 34 | JANE STREET GROUP, LLC | 224.9K +108.0K (+92.4%) | 1.69M +670.8K (+66.0%) | 0.40% +0.192 pp | 0.00% +0.000 pp | USD10.09 -25.7% | 13 qtrs — |
| 35 | PRIVIUM FUND MANAGEMENT B.V. | 210.0K +12.5K (+6.4%) | 1.58M -140.9K (-8.2%) | 0.37% +0.021 pp | 0.29% -0.019 pp | USD8.18 -8.3% | 10 qtrs — |
| 36 | WOODLINE PARTNERS LP | 200.0K +200.0K (+100.0%) | 1.50M +1.5M (+100.0%) | 0.36% +0.356 pp | 0.01% +0.006 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 37 | BARCLAYS PLC | 170.6K +55.8K (+48.6%) | 1.28M +38.3K (+3.1%) | 0.30% +0.099 pp | 0.00% +0.000 pp | USD10.99 -31.8% | 16 qtrs — |
| 38 | SCHONFELD STRATEGIC ADVISORS LLC | 162.0K -17.1K (-9.5%) | 1.21M -341.3K (-21.9%) | 0.29% -0.032 pp | 0.01% -0.004 pp | USD8.69 -13.7% | 2 qtrs — |
| 39 | NUVEEN, LLC | 158.8K +64.9K (+69.0%) | 1.19M +374.6K (+45.9%) | 0.28% +0.115 pp | 0.00% +0.000 pp | USD4.97 +50.9% | 4 qtrs — |
| 40 | DEKABANK DEUTSCHE GIROZENTRALE | 30.0K +— (+0.0%) | 1.17M +12.0K (+1.0%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD20.26 -63.0% | 9 qtrs — |
| 41 | INVESCO LTD. | 153.1K +26.6K (+21.0%) | 1.15M +48.6K (+4.4%) | 0.27% +0.047 pp | 0.00% +0.000 pp | USD7.39 +1.5% | 17 qtrs — |
| 42 | PERIGON WEALTH MANAGEMENT, LLC | 146.1K +— (+0.0%) | 1.10M -173.9K (-13.7%) | 0.26% -0.001 pp | 0.02% -0.006 pp | USD21.94 -65.8% | 17 qtrs — |
| 43 | BANK OF NEW YORK MELLON CORP | 136.7K -5.0K (-3.5%) | 1.03M -206.0K (-16.7%) | 0.24% -0.010 pp | 0.00% 0.000 pp | USD22.31 -66.4% | 20 qtrs — |
| 44 | WELLINGTON MANAGEMENT GROUP LLP | 130.3K -5.2K (-3.9%) | 976.9K -200.3K (-17.0%) | 0.23% -0.010 pp | 0.00% +0.000 pp | USD8.69 -13.7% | 17 qtrs — |
| 45 | ADAR1 CAPITAL MANAGEMENT, LLC | 116.7K +100.0K (+598.4%) | 875.3K +730.1K (+502.7%) | 0.21% +0.178 pp | 0.06% +0.051 pp | USD7.67 -2.2% | 2 qtrs — |
| 46 | D. E. SHAW & CO., INC. | 111.8K +101.7K (+1,007.1%) | 838.7K +750.9K (+855.5%) | 0.20% +0.181 pp | 0.00% +0.000 pp | USD9.53 -21.3% | 8 qtrs — |
| 47 | SILVERARC CAPITAL MANAGEMENT, LLC | 100.0K +100.0K (+100.0%) | 750.0K +750.0K (+100.0%) | 0.18% +0.178 pp | 0.10% +0.104 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 48 | MILLENNIUM MANAGEMENT LLC | 96.4K -1.1M (-91.6%) | 722.7K -9.3M (-92.8%) | 0.17% -1.884 pp | 0.00% -0.004 pp | USD5.81 +29.1% | 21 qtrs — |
| 49 | AMERICAN CENTURY COMPANIES INC | 91.1K +21.5K (+30.8%) | 683.1K +78.1K (+12.9%) | 0.16% +0.038 pp | 0.00% +0.000 pp | USD9.96 -24.7% | 7 qtrs — |
| 50 | RAFFERTY ASSET MANAGEMENT, LLC | 83.4K +83.4K (+100.0%) | 625.6K +625.6K (+100.0%) | 0.15% +0.149 pp | 0.00% +0.002 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 51 | ENGINEERS GATE MANAGER LP | 74.3K +74.3K (+100.0%) | 557.0K +557.0K (+100.0%) | 0.13% +0.132 pp | 0.01% +0.007 pp | USD7.50 +0.0% | 8 qtrs — |
| 52 | SQUAREPOINT OPS LLC | 71.7K +24.9K (+53.1%) | 537.9K +130.9K (+32.2%) | 0.13% +0.044 pp | 0.00% +0.000 pp | USD5.02 +49.4% | 3 qtrs — |
| 53 | FMR LLC | 65.6K +79.0 (+0.1%) | 492.4K -77.4K (-13.6%) | 0.12% 0.000 pp | 0.00% +0.000 pp | USD4.74 +58.2% | 21 qtrs — |
| 54 | XTX TOPCO LTD | 65.0K +25.0K (+62.6%) | 487.7K +140.2K (+40.4%) | 0.12% +0.044 pp | 0.01% -0.005 pp | USD5.17 +45.1% | 5 qtrs — |
| 55 | ALLIANCEBERNSTEIN L.P. | 55.1K -10.2K (-15.6%) | 413.3K -154.1K (-27.2%) | 0.10% -0.019 pp | 0.00% +0.000 pp | USD18.50 -59.5% | 13 qtrs — |
| 56 | RHUMBLINE ADVISERS | 53.8K -10.3K (-16.1%) | 403.8K -153.9K (-27.6%) | 0.10% -0.019 pp | 0.00% 0.000 pp | USD20.61 -63.6% | 20 qtrs — |
| 57 | PRINCIPIA WEALTH ADVISORY, LLC | 53.7K +53.7K (+100.0%) | 402.5K +402.5K (+100.0%) | 0.10% +0.096 pp | 0.25% +0.252 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 58 | WALLEYE CAPITAL LLC | 50.8K +50.8K (+100.0%) | 380.7K +380.7K (+100.0%) | 0.09% +0.090 pp | 0.00% +0.001 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 59 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 50.0K +— (+0.0%) | 375.0K -59.5K (-13.7%) | 0.09% 0.000 pp | 0.01% -0.001 pp | USD6.08 +23.4% | 4 qtrs — |
| 60 | PANAGORA ASSET MANAGEMENT INC | 47.0K +— (+0.0%) | 352.3K -55.9K (-13.7%) | 0.08% 0.000 pp | 0.00% 0.000 pp | USD8.69 -13.7% | 2 qtrs — |
| 61 | WELLS FARGO & COMPANY/MN | 46.6K +15.6K (+50.4%) | 349.7K +80.4K (+29.8%) | 0.08% +0.028 pp | 0.00% +0.000 pp | USD11.54 -35.0% | 20 qtrs — |
| 62 | QUANTINNO CAPITAL MANAGEMENT LP | 46.3K +10.9K (+30.6%) | 347.3K +39.2K (+12.7%) | 0.08% +0.019 pp | 0.00% 0.000 pp | USD8.41 -10.8% | 2 qtrs — |
| 63 | DECHENG CAPITAL LLC | 44.3K -48.4K (-52.2%) | 332.3K -473.6K (-58.8%) | 0.08% -0.087 pp | 0.04% -0.096 pp | USD27.48 -72.7% | 8 qtrs — |
| 64 | CREATIVE PLANNING | 44.2K +6.5K (+17.2%) | 331.5K +3.8K (+1.1%) | 0.08% +0.011 pp | 0.00% +0.000 pp | USD8.52 -12.0% | 2 qtrs — |
| 65 | JAIN GLOBAL LLC | 40.5K +40.5K (+100.0%) | 303.5K +303.5K (+100.0%) | 0.07% +0.072 pp | 0.00% +0.002 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 66 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 39.2K +39.2K (+100.0%) | 293.8K +293.8K (+100.0%) | 0.07% +0.070 pp | 0.00% +0.002 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 67 | PRICE T ROWE ASSOCIATES INC /MD/ | 38.7K -6.3K (-13.9%) | 291.0K -101.0K (-25.8%) | 0.07% -0.012 pp | 0.00% +0.000 pp | USD13.03 -42.4% | 17 qtrs — |
| 68 | RANGELEY CAPITAL, LLC | 38.7K -4.0K (-9.4%) | 290.0K -80.8K (-21.8%) | 0.07% -0.007 pp | 0.24% -0.080 pp | USD7.17 +4.6% | 3 qtrs — |
| 69 | AQR CAPITAL MANAGEMENT LLC | 36.1K +180.0 (+0.5%) | 270.6K -41.4K (-13.3%) | 0.06% +0.000 pp | 0.00% 0.000 pp | USD4.90 +53.1% | 4 qtrs — |
| 70 | JUMP FINANCIAL, LLC | 33.8K +33.8K (+100.0%) | 253.7K +253.7K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.003 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 71 | TUDOR INVESTMENT CORP ET AL | 31.8K +6.0K (+23.5%) | 238.6K +14.7K (+6.6%) | 0.06% +0.011 pp | 0.00% +0.000 pp | USD14.41 -48.0% | 7 qtrs — |
| 72 | PROFUND ADVISORS LLC | 30.9K +30.9K (+100.0%) | 231.4K +231.4K (+100.0%) | 0.06% +0.055 pp | 0.01% +0.007 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 73 | AXQ CAPITAL, LP | 30.8K +17.9K (+138.8%) | 230.7K +118.7K (+106.1%) | 0.05% +0.032 pp | 0.05% +0.009 pp | USD8.00 -6.3% | 2 qtrs — |
| 74 | ACADIAN ASSET MANAGEMENT LLC | 30.1K -25.0K (-45.3%) | 225.0K -253.0K (-52.9%) | 0.05% -0.045 pp | 0.00% -0.001 pp | USD3.42 +119.3% | 5 qtrs — |
| 75 | HARBOR CAPITAL ADVISORS, INC. | 29.7K +17.8K (+149.7%) | 223.0K +120.0K (+116.5%) | 0.05% +0.032 pp | 0.02% +0.009 pp | USD5.79 +29.5% | 4 qtrs — |
| 76 | THRIVENT FINANCIAL FOR LUTHERANS | 28.9K +28.9K (+100.0%) | 217.0K +217.0K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.000 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 77 | KERA CAPITAL PARTNERS, INC. | 24.1K +— (+0.0%) | 213.2K +4.1K (+2.0%) | 0.04% 0.000 pp | 0.03% -0.005 pp | USD3.71 +102.2% | 3 qtrs — |
| 78 | MARSHALL WACE, LLP | 27.8K -118.1K (-81.0%) | 208.2K -1.1M (-83.6%) | 0.05% -0.211 pp | 0.00% -0.001 pp | USD8.90 -15.7% | 8 qtrs — |
| 79 | MAN GROUP PLC | 27.0K +8.5K (+46.2%) | 202.8K +42.1K (+26.2%) | 0.05% +0.015 pp | 0.00% +0.000 pp | USD4.78 +56.9% | 4 qtrs — |
| 80 | STRS OHIO | 25.1K +— (+0.0%) | 188.3K -29.9K (-13.7%) | 0.04% 0.000 pp | 0.00% 0.000 pp | USD8.69 -13.7% | 2 qtrs — |
| 81 | METLIFE INVESTMENT MANAGEMENT, LLC | 25.1K +6.7K (+36.4%) | 188.2K +28.3K (+17.7%) | 0.04% +0.012 pp | 0.00% +0.000 pp | USD13.64 -45.0% | 20 qtrs — |
| 82 | PELOTON WEALTH STRATEGISTS | 25.0K +— (+0.0%) | 188.0K -29.0K (-13.4%) | 0.04% 0.000 pp | 0.07% -0.013 pp | USD12.73 -41.1% | 15 qtrs — |
| 83 | TRUIST FINANCIAL CORP | 25.0K +25.0K (+100.0%) | 187.5K +187.5K (+100.0%) | 0.04% +0.045 pp | 0.00% +0.000 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 84 | VIRTUS INVESTMENT ADVISERS, INC. | 24.5K +24.5K (+100.0%) | 184.1K +184.1K (+100.0%) | 0.04% +0.044 pp | 0.05% +0.050 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 85 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 23.5K +4.6K (+24.5%) | 176.9K +12.7K (+7.7%) | 0.04% +0.008 pp | 0.00% +0.000 pp | USD16.92 -55.7% | 7 qtrs — |
| 86 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 23.8K +23.8K (+100.0%) | 174.5K +174.5K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 87 | ENTRYPOINT CAPITAL, LLC | 22.3K +22.3K (+100.0%) | 167.4K +167.4K (+100.0%) | 0.04% +0.040 pp | 0.07% +0.065 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 88 | PDT PARTNERS, LLC | 20.1K +— (+0.0%) | 150.7K -23.9K (-13.7%) | 0.04% 0.000 pp | 0.01% -0.001 pp | USD5.57 +34.6% | 8 qtrs — |
| 89 | COMMONWEALTH EQUITY SERVICES, LLC | 20.0K +20.0K (+100.0%) | 150.1K +150.1K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.000 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 90 | CITADEL ADVISORS LLC | 19.9K +19.9K (+100.0%) | 149.2K +149.2K (+100.0%) | 0.04% +0.035 pp | 0.00% +0.000 pp | USD7.50 +0.0% | 21 qtrs — |
| 91 | LANDING POINT FINANCIAL GROUP, LLC | 19.0K +19.0K (+100.0%) | 142.5K +142.5K (+100.0%) | 0.03% +0.034 pp | 0.07% +0.071 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 92 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 18.1K +17.9K (+14,343.2%) | 135.4K +134.3K (+12,368.2%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD7.51 -0.1% | 2 qtrs — |
| 93 | POLYMER CAPITAL MANAGEMENT (US) LLC | 18.0K +18.0K (+100.0%) | 135.3K +135.3K (+100.0%) | 0.03% +0.032 pp | 0.01% +0.014 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 94 | PARALLEL ADVISORS, LLC | 17.9K -1.9K (-9.4%) | 134.2K -37.4K (-21.8%) | 0.03% -0.003 pp | 0.00% -0.001 pp | USD21.34 -64.9% | 9 qtrs — |
| 95 | INTECH INVESTMENT MANAGEMENT LLC | 17.6K -1.0K (-5.5%) | 132.2K -29.9K (-18.4%) | 0.03% -0.002 pp | 0.00% 0.000 pp | USD7.44 +0.8% | 6 qtrs — |
| 96 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 16.9K +16.9K (+100.0%) | 126.8K +126.8K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD7.50 +0.0% | 1 qtrs NEW |
| 97 | BALLENTINE PARTNERS, LLC | 16.5K +170.0 (+1.0%) | 124.0K -18.2K (-12.8%) | 0.03% +0.000 pp | 0.00% 0.000 pp | USD8.68 -13.6% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 87 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.86% | 493.9K | 0.65% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.33% | 702.8K | 0.50% |
| 3 | Xtrackers Bloomberg Commodity ex-Agriculture & Livestock Swap UCITS ETF 2C XBCU.L | 0.29% | 2.23M | 0.29% |
| 4 | Xtrackers Bloomberg Commodity ex-Agriculture & Livestock Swap UCITS ETF 3C GBP Hedged XDBG.L | 0.29% | 2.23M | 0.39% |
| 5 | State Street SPDR S&P Biotech ETF XBI | 0.18% | 19.86M | 0.35% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 0.18% | 65.6K | 0.45% |
| 7 | iShares Micro-Cap ETF IWC | 0.13% | 1.90M | 0.60% |
| 8 | State Street SPDR S&P Kensho New Economies Composite ETF KOMP | 0.12% | 3.38M | 0.20% |
| 9 | Vanguard U.S. Momentum Factor ETF VFMO | 0.08% | 1.39M | 0.13% |
| 10 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.06% | 56.3K | 0.89% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.50
Neutral
Ratio by volume
3.00
Bullish
Buys
6
Sells
4
Shares acquired
1.23M
Shares disposed
1.5K
Cash buys
—
Cash sales
2.00
Net activity
+1,230,610
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-25 | Simms Christopher Paul | Officer | A-Award | A | Stock Option (Right to Buy) | 219,000 | 9.88 | 2.16M | 219,000 | D | ↗ |
| 2026-03-25 | Kirn David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 9.88 | 7.41M | 750,000 | D | ↗ |
| 2026-03-25 | Bizily Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 217,000 | 9.88 | 2.14M | 217,000 | D | ↗ |
| 2026-03-20 | Gupta Ashoo | Officer | M-Exempt | A | Common Stock | 865 | 0.00 | — | 47,224 | D | ↗ |
| 2026-01-05 | SBLENDORIO GLENN | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 7.30 | 328.5K | 45,000 | D | ↗ |
| 2025-12-20 | Gupta Ashoo | Officer | S-Sale | D | Common Stock | 310 | 8.68 | 2.7K | 46,218 | D | ↗ |
| 2025-12-16 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,635 | 4.14 | 6.8K | 73,595 | D | ↗ |
| 2025-12-12 | THEUER CHARLES | Director | M-Exempt | D | Stock Option (Right to Buy) | 9,333 | 1.14 | 10.6K | 0 | D | ↗ |
| 2025-12-09 | Simms Christopher Paul | Officer | — | — | Stock Option (Right to Buy) | 300,000 | 9.38 | 2.81M | 0 | D | ↗ |
| 2025-12-09 | Humer Kristian | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-11-17 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,635 | 4.14 | 6.8K | 75,230 | D | ↗ |
| 2025-10-24 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,084 | 6.49 | 7.0K | 9,295 | D | ↗ |
| 2025-10-16 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,635 | 4.14 | 6.8K | 76,865 | D | ↗ |
| 2025-10-09 | Bizily Scott | Officer | S-Sale | D | Common Stock | 2,408 | 10.00 | 24.1K | 5,188 | D | ↗ |
| 2025-09-30 | Gupta Ashoo | Officer | — | — | Stock Option (Right to Buy) | 27,700 | 22.69 | 628.5K | 0 | D | ↗ |
| 2025-09-23 | Bizily Scott | Officer | S-Sale | D | Common Stock | 2,407 | 8.00 | 19.3K | 7,596 | D | ↗ |
| 2025-06-17 | Tomasello Shawn | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 4.15 | 93.4K | 22,500 | D | ↗ |
| 2025-06-17 | THEUER CHARLES | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 4.15 | 93.4K | 22,500 | D | ↗ |
| 2025-06-17 | Miller-Rich Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 4.15 | 93.4K | 22,500 | D | ↗ |
| 2025-06-17 | MILLIGAN JOHN F | Director | A-Award | A | Stock Option (Right to Buy) | 33,750 | 4.15 | 140.1K | 33,750 | D | ↗ |
| 2025-06-17 | GRAY SUSANNAH | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 4.15 | 93.4K | 22,500 | D | ↗ |
| 2025-06-17 | Chacko Jacob | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 4.15 | 93.4K | 22,500 | D | ↗ |
| 2025-03-06 | Mehra Uneek | Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 4.14 | 538.2K | 130,000 | D | ↗ |
| 2025-03-06 | Kirn David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 267,500 | 4.14 | 1.11M | 267,500 | D | ↗ |
| 2025-03-06 | Kim Robert Young | Officer | A-Award | A | Stock Option (Right to Buy) | 92,300 | 4.14 | 382.1K | 92,300 | D | ↗ |
| 2025-03-06 | Kamal Fariborz | Officer | A-Award | A | Stock Option (Right to Buy) | 178,400 | 4.14 | 738.6K | 178,400 | D | ↗ |
| 2025-03-06 | Bizily Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 78,500 | 4.14 | 325.0K | 78,500 | D | ↗ |
| 2024-12-09 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | J-Other | D | Common Stock | 535,000 | 0.00 | — | 4,563,211 | I | ↗ |
| 2024-11-13 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | — | — | Warrant (Right to Buy) | 3,075,000 | 0.00 | 307.50 | 0 | I | ↗ |
| 2024-11-08 | BVF PARTNERS L P/IL | Other | J-Other | D | Common Stock, $0.0001 par value | 240,000 | 0.00 | — | 87,911 | D | ↗ |
| 2024-09-16 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right To Buy) | 500 | 6.49 | 3.2K | 10,379 | — | ↗ |
| 2024-08-19 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right To Buy) | 500 | 6.49 | 3.2K | 10,879 | — | ↗ |
| 2024-07-22 | BVF PARTNERS L P/IL | 10% Owner | — | D | Common Stock, $0.0001 par value | 0 | 0.00 | — | 3,892,237 | — | ↗ |
| 2024-07-16 | Bizily Scott | Officer | M-Exempt | A | Common Stock | 1,250 | 8.04 | 10.1K | 8,531 | — | ↗ |
| 2024-07-11 | Bizily Scott | Officer | M-Exempt | A | Common Stock | 1,996 | 15.78 | 31.5K | 8,777 | — | ↗ |
| 2024-07-10 | Kirn David | Director / Officer | M-Exempt | A | Common Stock | 1,270 | 15.78 | 20.0K | 1,072,076 | — | ↗ |
| 2024-07-01 | Bizily Scott | Officer | M-Exempt | A | Common Stock | 2,916 | 8.04 | 23.4K | 5,985 | — | ↗ |
| 2024-06-24 | Kirn David | Director / Officer | M-Exempt | A | Common Stock | 12,930 | 14.42 | 186.5K | 1,072,083 | — | ↗ |
| 2024-06-17 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right To Buy) | 1,250 | 8.04 | 10.1K | 36,668 | — | ↗ |
| 2024-05-21 | Tomasello Shawn | Director | A-Award | A | Stock Option (Right To Buy) | 22,500 | 25.15 | 565.9K | 22,500 | — | ↗ |
| 2024-05-21 | THEUER CHARLES | Director | A-Award | A | Stock Option (Right To Buy) | 22,500 | 25.15 | 565.9K | 22,500 | — | ↗ |
| 2024-05-21 | Miller-Rich Nancy | Director | A-Award | A | Stock Option (Right To Buy) | 22,500 | 25.15 | 565.9K | 22,500 | — | ↗ |
| 2024-05-21 | MILLIGAN JOHN F | Director | A-Award | A | Stock Option (Right To Buy) | 26,791 | 25.15 | 673.8K | 26,791 | — | ↗ |
| 2024-05-21 | GRAY SUSANNAH | Director | A-Award | A | Stock Option (Right To Buy) | 22,500 | 25.15 | 565.9K | 22,500 | — | ↗ |
| 2024-05-21 | Chacko Jacob | Director | A-Award | A | Stock Option (Right To Buy) | 22,500 | 25.15 | 565.9K | 22,500 | — | ↗ |
| 2024-05-16 | Bizily Scott | Officer | M-Exempt | A | Common Stock | 1,250 | 8.04 | 10.1K | 3,487 | — | ↗ |
| 2024-04-16 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right To Buy) | 1,250 | 8.04 | 10.1K | 39,168 | — | ↗ |
| 2024-04-01 | Bizily Scott | Officer | M-Exempt | A | Common Stock | 1,996 | 15.78 | 31.5K | 7,981 | — | ↗ |
| 2024-03-27 | Bizily Scott | Officer | S-Sale | D | Common Stock | 5,833 | 35.04 | 204.4K | 1,737 | — | ↗ |
| 2024-03-18 | Bizily Scott | Officer | M-Exempt | A | Common Stock | 1,250 | 8.04 | 10.1K | 3,487 | — | ↗ |
| 2024-02-27 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right To Buy) | 1,909 | 20.24 | 38.6K | 48,091 | — | ↗ |
| 2024-02-16 | Bizily Scott | Officer | S-Sale | D | Common Stock | 1,750 | 27.67 | 48.4K | 1,737 | — | ↗ |
| 2024-02-08 | Kirn David | Director / Officer | S-Sale | D | Common Stock | 92,001 | 27.13 | 2.50M | 1,059,153 | — | ↗ |
| 2024-02-08 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,916 | 8.04 | 23.4K | 45,834 | — | ↗ |
| 2024-02-07 | Kim Robert Young | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,595 | — | ↗ |
| 2024-02-05 | Kim Robert Young | Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,000 | 18.66 | 223.9K | 138,000 | — | ↗ |
| 2024-01-23 | Kirn David | Director / Officer | S-Sale | D | Common Stock | 5,696 | 18.41 | 104.9K | 1,151,154 | — | ↗ |
| 2024-01-05 | Kirn David | Director / Officer | S-Sale | D | Common Stock | 28,104 | 19.56 | 549.8K | 1,156,983 | — | ↗ |
| 2024-01-04 | VIKING GLOBAL INVESTORS LP | 10% Owner | S-Sale | D | Common Stock | 540,000 | 19.53 | 10.55M | 4,247,914 | — | ↗ |
| 2024-01-04 | Kirn David | Director / Officer | S-Sale | D | Common Stock | 40,732 | 20.31 | 827.2K | 1,185,087 | — | ↗ |
| 2023-12-18 | Kirn David | Director / Officer | S-Sale | D | Common Stock | 4,702 | 18.13 | 85.2K | 1,225,819 | — | ↗ |
| 2023-12-15 | Kirn David | Director / Officer | S-Sale | D | Common Stock | 28,632 | 17.27 | 494.4K | 1,230,521 | — | ↗ |
| 2023-12-11 | Mehra Uneek | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 14.42 | 1.08M | 75,000 | — | ↗ |
| 2023-12-11 | Kirn David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 590,000 | 14.42 | 8.51M | 590,000 | — | ↗ |
| 2023-12-11 | Kim Robert Young | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 14.42 | 3.61M | 250,000 | — | ↗ |
| 2023-12-11 | Kamal Fariborz | Officer | A-Award | A | Stock Option (Right to Buy) | 260,000 | 14.42 | 3.75M | 260,000 | — | ↗ |
| 2023-12-11 | Bizily Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 14.42 | 1.87M | 130,000 | — | ↗ |
| 2023-10-01 | Mehra Uneek | Officer | A-Award | A | Stock Option (Right to Buy) | 229,634 | 12.73 | 2.92M | 229,634 | — | ↗ |
| 2023-09-22 | Mehra Uneek | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-08 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,750 | 8.04 | 30.2K | 48,750 | — | ↗ |
| 2023-06-01 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,875 | 6.49 | 12.2K | 18,375 | — | ↗ |
| 2023-05-23 | Tomasello Shawn | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 17.98 | 404.6K | 22,500 | — | ↗ |
| 2023-05-23 | THEUER CHARLES | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 17.98 | 404.6K | 22,500 | — | ↗ |
| 2023-05-23 | Miller-Rich Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 17.98 | 404.6K | 22,500 | — | ↗ |
| 2023-05-23 | MILLIGAN JOHN F | Director | A-Award | A | Stock Option (Right to Buy) | 33,750 | 17.98 | 606.8K | 33,750 | — | ↗ |
| 2023-05-23 | Kasahara Noriyuki | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 17.98 | 404.6K | 22,500 | — | ↗ |
| 2023-05-23 | GRAY SUSANNAH | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 17.98 | 404.6K | 22,500 | — | ↗ |
| 2023-05-23 | Chacko Jacob | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 17.98 | 404.6K | 22,500 | — | ↗ |
| 2023-05-15 | Moretti August J | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 9.41 | 28.2K | 217,060 | — | ↗ |
| 2023-05-09 | VIKING GLOBAL INVESTORS LP | 10% Owner | P-Purchase | A | Common Stock | 850,000 | 16.00 | 13.60M | 4,787,914 | — | ↗ |
| 2023-05-02 | Kirn David | Director / Officer | G-Gift | D | Common Stock | 600,000 | 0.00 | — | 1,259,153 | — | ↗ |
| 2023-04-21 | Chacko Jacob | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 9.41 | 47.1K | 32,500 | — | ↗ |
| 2023-04-21 | Bizily Scott | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,750 | 8.04 | 30.2K | 52,500 | — | ↗ |
| 2023-03-24 | Kim Robert Young | Officer | — | D | Stock Options (Right to Buy) | 70,000 | 15.78 | 1.10M | 0 | — | ↗ |
| 2023-03-01 | Bizily Scott | Officer | S-Sale | D | Common Stock | 2,248 | 19.30 | 43.4K | 2,109 | — | ↗ |
| 2023-02-22 | Kirn David | Director / Officer | S-Sale | D | Common Stock | 16,449 | 20.22 | 332.7K | 1,859,153 | — | ↗ |
| 2023-02-21 | Kirn David | Director / Officer | S-Sale | D | Common Stock | 17,090 | 20.93 | 357.7K | 1,876,509 | — | ↗ |
| 2023-02-10 | Moretti August J | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 20.24 | 1.01M | 50,000 | — | ↗ |
| 2023-02-10 | Kirn David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 222,000 | 20.24 | 4.49M | 222,000 | — | ↗ |
| 2023-02-10 | Kamal Fariborz | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 20.24 | 1.52M | 75,000 | — | ↗ |
| 2023-02-10 | Bizily Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 20.24 | 1.01M | 50,000 | — | ↗ |
| 2023-01-20 | Kirn David | Officer | S-Sale | D | Common Stock | 8,625 | 20.19 | 174.1K | 1,893,599 | — | ↗ |
| 2023-01-19 | Kirn David | Officer | S-Sale | D | Common Stock | 10,899 | 20.03 | 218.3K | 1,902,224 | — | ↗ |
| 2022-12-21 | Moretti August J | Officer | M-Exempt | A | Common Stock | 3,000 | 9.41 | 28.2K | 6,595 | — | ↗ |
| 2022-12-16 | Kirn David | Officer | S-Sale | D | Common Stock | 27,595 | 22.66 | 625.4K | 1,939,472 | — | ↗ |
| 2022-12-15 | Kirn David | Officer | S-Sale | D | Common Stock | 31,433 | 23.56 | 740.6K | 1,968,567 | — | ↗ |
| 2022-12-01 | Bizily Scott | Officer | S-Sale | D | Common Stock | 400 | 21.52 | 8.6K | 4,332 | — | ↗ |
| 2022-09-23 | Kasahara Noriyuki | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 8.06 | 362.7K | 45,000 | — | ↗ |
| 2022-09-23 | Kamal Fariborz | Officer | A-Award | A | Stock Option (Right to Buy) | 15,000 | 8.06 | 120.9K | 15,000 | — | ↗ |
| 2022-09-01 | Moretti August J | Officer | A-Award | D | Stock Option (Right to Buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-09-01 | Kamal Fariborz | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-09-01 | FISHMAN ROBERT S | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-09-01 | Bizily Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-06-18 | Bizily Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-06-16 | BVF PARTNERS L P/IL | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,132,411 | — | ↗ |
| 2022-05-23 | Tomasello Shawn | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-23 | THEUER CHARLES | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-23 | Miller-Rich Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 7.77 | 174.8K | 22,500 | — | ↗ |
| 2022-05-23 | MILLIGAN JOHN F | Director | A-Award | A | Stock Option (Right to Buy) | 33,750 | 0.00 | — | 33,750 | — | ↗ |
| 2022-05-23 | GRAY SUSANNAH | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-05-23 | Chacko Jacob | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-02-01 | Zimmermann Carolyne | Officer | A-Award | A | Stock Option (Right to Buy) | 35,000 | 15.78 | 552.3K | 35,000 | — | ↗ |
| 2022-02-01 | Moretti August J | Officer | A-Award | D | Stock Option (Right to Buy) | 65,000 | 15.78 | 1.03M | 65,000 | — | ↗ |
| 2022-02-01 | Kirn David | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 150,000 | 15.78 | 2.37M | 150,000 | — | ↗ |
| 2022-02-01 | Kamal Fariborz | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 15.78 | 1.10M | 70,000 | — | ↗ |
| 2022-02-01 | FISHMAN ROBERT S | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 15.78 | 1.03M | 65,000 | — | ↗ |
| 2021-10-22 | SCHAFFER DAVID | Director | S-Sale | D | Common Stock | 1,900 | 31.00 | 58.9K | 901,215 | — | ↗ |
| 2021-10-21 | SCHAFFER DAVID | Director | S-Sale | D | Common Stock | 22,820 | 31.56 | 720.2K | 903,115 | — | ↗ |
| 2021-10-20 | SCHAFFER DAVID | Director | S-Sale | D | Common Stock | 11,565 | 31.02 | 358.8K | 925,935 | — | ↗ |
| 2021-09-30 | SCHAFFER DAVID | Director | S-Sale | D | Common Stock | 7,836 | 26.69 | 209.2K | 942,049 | — | ↗ |
| 2021-09-29 | SCHAFFER DAVID | Director | S-Sale | D | Common Stock | 7,806 | 27.99 | 218.5K | 958,950 | — | ↗ |
| 2021-09-28 | SCHAFFER DAVID | Director | S-Sale | D | Common Stock | 13,812 | 30.52 | 421.5K | 966,856 | — | ↗ |
| 2021-09-27 | SCHAFFER DAVID | Director | S-Sale | D | Common Stock | 6,157 | 33.51 | 206.3K | 980,768 | — | ↗ |
| 2021-06-07 | Zimmermann Carolyne | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 26.83 | 1.61M | 60,000 | — | ↗ |
| 2021-05-17 | Tomasello Shawn | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 26.89 | 605.0K | 22,500 | — | ↗ |
| 2021-05-17 | THEUER CHARLES | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 26.89 | 605.0K | 22,500 | — | ↗ |
| 2021-05-17 | SCHAFFER DAVID | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 26.89 | 605.0K | 22,500 | — | ↗ |
| 2021-05-17 | Miller-Rich Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 26.89 | 605.0K | 22,500 | — | ↗ |
| 2021-05-17 | MILLIGAN JOHN F | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 26.89 | 605.0K | 22,500 | — | ↗ |
| 2021-05-17 | GRAY SUSANNAH | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 26.89 | 605.0K | 22,500 | — | ↗ |
| 2021-05-17 | Chacko Jacob | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 26.89 | 605.0K | 22,500 | — | ↗ |
| 2021-04-12 | Moretti August J | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,000 | 9.41 | 9.4K | 223,060 | — | ↗ |
| 2021-03-08 | Moretti August J | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 41.66 | 2.92M | 70,000 | — | ↗ |
| 2021-03-08 | Kirn David | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 150,000 | 41.66 | 6.25M | 150,000 | — | ↗ |
| 2021-03-08 | Kamal Fariborz | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 41.66 | 2.50M | 60,000 | — | ↗ |
| 2020-12-15 | YAO TONY DUNG LING | Director | C-Conversion | A | Common Stock | 2,864 | 0.00 | — | 2,864 | — | ↗ |
| 2020-12-15 | VIKING GLOBAL INVESTORS LP | 10% Owner | P-Purchase | A | Common Stock | 1,100,000 | 23.00 | 25.30M | 3,937,914 | — | ↗ |
| 2020-12-15 | MILLIGAN JOHN F | Director | P-Purchase | A | Common Stock | 100,000 | 23.00 | 2.30M | 100,000 | — | ↗ |
| 2020-12-15 | Kamal Fariborz | Officer | P-Purchase | A | Common Stock | 4,347 | 23.00 | 100.0K | 4,347 | — | ↗ |
| 2020-12-10 | YAO TONY DUNG LING | Director | — | D | Series B Preferred Stock | 2,864 | 17.46 | 50.0K | 0 | — | ↗ |
| 2020-12-10 | VIKING GLOBAL INVESTORS LP | 10% Owner | — | I | Series C Redeemable Convertible Preferred Stock | 833,333 | 0.00 | — | 0 | — | ↗ |
| 2020-12-10 | Tomasello Shawn | Director | — | D | Stock Option (Right to Buy) | 45,000 | 18.66 | 839.7K | 0 | — | ↗ |
| 2020-12-10 | THEUER CHARLES | Director | — | D | Stock Option (Right to Buy) | 13,684 | 3.19 | 43.7K | 0 | — | ↗ |
| 2020-12-10 | SCHAFFER DAVID | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,000,000 | — | ↗ |
| 2020-12-10 | Moretti August J | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,000 | — | ↗ |
| 2020-12-10 | Miller-Rich Nancy | Director | — | D | Stock Option (Right to Buy) | 45,000 | 18.66 | 839.7K | 0 | — | ↗ |
| 2020-12-10 | MILLIGAN JOHN F | Director | — | D | Stock Option (Right to Buy) | 335,243 | 15.97 | 5.35M | 0 | — | ↗ |
| 2020-12-10 | Kirn David | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,000,000 | — | ↗ |
| 2020-12-10 | Kamal Fariborz | Officer | — | D | Stock Option (Right to Buy) | 71,930 | 8.27 | 594.9K | 0 | — | ↗ |
| 2020-12-10 | GRAY SUSANNAH | Director | — | D | Stock Option (Right to Buy) | 45,000 | 15.97 | 718.7K | 0 | — | ↗ |
| 2020-12-10 | FISHMAN ROBERT S | Officer | — | D | Stock Option (Right to Buy) | 240,000 | 18.66 | 4.48M | 0 | — | ↗ |
| 2020-12-10 | Chacko Jacob | Director | — | D | Stock Option (Right to Buy) | 22,500 | 15.10 | 339.8K | 0 | — | ↗ |
| 2020-12-10 | Burkoth William T. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-702.9K
Shares Outstanding
52.27M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Kristian Humer Chief Financial Officer | 66.0K | 50.0K | — | 3.87M | — | 247.00 | 3.99M | 97.09% | ↗ |
| 2 | 2025 | David Kirn, M.D. President and Chief Executive Officer | 667.3K | — | — | 822.8K | 560.6K | 744.00 | 2.05M | 40.11% | ↗ |
| 3 | 2025 | Fariborz Kamal, Ph.D. Former Chief Operating Officer & President | 551.7K | — | — | 548.7K | 339.5K | 1.6K | 1.44M | 38.06% | ↗ |
| 4 | 2024 | David Kirn, M.D. President and Chief Executive Officer | 662.8K | — | — | — | 292.7K | 53.6K | 1.01M | 0.00% | ↗ |
| 5 | 2024 | David Kirn, M.D. Chief Executive Officer | 662.8K | — | — | — | 292.7K | 53.6K | 1.01M | 0.00% | ↗ |
| 6 | 2024 | Uneek Mehra Chief Financial and Business Officer | 545.8K | 100.0K | — | — | 178.1K | — | 823.9K | 0.00% | ↗ |
| 7 | 2024 | Fariborz Kamal, Ph.D. Former Chief Operating Officer & President | 546.3K | — | — | — | 180.6K | 7.7K | 734.6K | 0.00% | ↗ |
| 8 | 2024 | Fariborz Kamal, Ph.D. Chief Operating Officer & President | 546.3K | — | — | — | 180.6K | 7.7K | 734.6K | 0.00% | ↗ |
| 9 | 2023 | David Kirn, M.D. Chief Executive Officer | 596.6K | — | — | 9.28M | 395.0K | 16.5K | 10.29M | 90.20% | ↗ |
| 10 | 2023 | Fariborz Kamal, Ph.D. Chief Operating Officer & President | 489.4K | — | — | 3.76M | 296.8K | — | 4.54M | 82.70% | ↗ |
| 11 | 2023 | Robert Kim, M.D. Chief Medical Officer | 456.1K | — | — | 3.26M | 232.3K | 16.5K | 3.96M | 82.22% | ↗ |
| 12 | 2022 | David Kirn, M.D. Chief Executive Officer | 585.7K | — | — | 2.37M | 321.8K | 13.5K | 3.29M | 71.99% | ↗ |
| 13 | 2022 | Fariborz Kamal, Ph.D. Chief Operating Officer & President | 469.0K | — | — | 1.71M | 209.4K | — | 2.39M | 71.57% | ↗ |
| 14 | 2022 | August J. Moretti, J.D. Chief Financial Officer | 459.6K | — | — | 1.51M | 192.7K | 13.5K | 2.17M | 69.37% | ↗ |
| 15 | 2021 | David Kirn, M.D. Chief Executive Officer | 570.0K | — | — | 4.39M | 228.0K | 13.0K | 5.20M | 84.41% | ↗ |
| 16 | 2021 | August J. Moretti, J.D. Chief Financial Officer | 435.0K | — | — | 2.05M | 139.2K | 13.0K | 2.64M | 77.72% | ↗ |
| 17 | 2021 | August Moretti Chief Financial Officer | 435.0K | — | — | 2.05M | 139.2K | 13.0K | 2.64M | 77.72% | ↗ |
| 18 | 2021 | Theresa Janke Chief of Staff | 385.0K | — | — | 2.05M | 129.4K | 9.8K | 2.57M | 79.63% | ↗ |
| 19 | 2020 | Robert Fishman, M.D. Chief Medical Officer | 89.7K | 50.0K | — | 3.16M | 44.9K | — | 3.34M | 94.47% | ↗ |
| 20 | 2020 | David Kirn, M.D. Chief Executive Officer | 451.2K | — | — | — | 237.3K | 13.0K | 701.5K | 0.00% | ↗ |
| 21 | 2020 | August Moretti Chief Financial Officer | 399.7K | — | — | — | 220.1K | 13.0K | 632.8K | 0.00% | ↗ |
| 22 | 2019 | August Moretti Chief Financial Officer | 374.2K | — | — | 1.66M | 89.7K | 12.5K | 2.14M | 77.71% | ↗ |
| 23 | 2019 | David Kirn, M.D. Chief Executive Officer | 430.0K | — | — | — | 111.8K | 12.5K | 554.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David H. Kirn | Co-Founder, President, CEO & Director | 1M | — |
| Fariborz Kamal | Chief Technical Advisor | 892.9K | — |
| Theresa Janke | Co-Founder & Chief of Staff | 652.3K | female |
| Noriyuki Kasahara | Chief Scientific Advisor & Member of Scientific Advisory Board | 201.3K | — |
| John F. Milligan | Executive Chairman | 150.0K | — |
| Kristian Humer | CFO and Principal Financial & Accounting Officer | 116.2K | male |
| Julian Pei | Head of Investor Relations & Corporate Finance | — | — |
| Ashoo Gupta | Principal Accounting Officer & Principal Financial Officer | — | male |
| An Song | Chief Translational Medicine Advisor | — | — |
| Katy Barglow | Chief Technical Officer | — | — |
| Scott Bizily | Chief Legal Officer & Corporate Secretary | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FDMT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
